SHC

Sotera Health Co

15 filings tracked

healthcarehealthcare equipmentMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 22

Re-election of Class III directors maintains current board composition.

management change

30%

bullishMay 22

Strong shareholder approval of executive compensation and auditor ratification.

regulatory action

60%

neutralMay 22

Re-election of Class III directors maintains current board composition.

management change

30%

bullishMay 22

Strong shareholder approval of executive compensation and auditor ratification.

regulatory action

60%

neutralMay 22

Re-election of Class III directors maintains current board composition.

management change

30%

bullishMay 22

Strong shareholder approval of executive compensation and auditor ratification.

regulatory action

60%

neutralMay 22

Re-election of Class III directors maintains current board composition.

management change

30%

bullishMay 22

Strong shareholder approval of executive compensation and auditor ratification.

regulatory action

60%

neutralMay 22

Re-election of Class III directors maintains current board composition.

management change

30%

bullishMay 22

Strong shareholder approval of executive compensation and auditor ratification.

regulatory action

60%

neutralMay 22

Re-election of Class III directors maintains current board composition.

management change

30%

bullishMay 22

Strong shareholder approval of executive compensation and auditor ratification.

regulatory action

60%

neutralMay 13

Termination of stockholders agreement ends PE-led board designation rights.

management change

60%

bearishMay 13

Complete exit of major private equity sponsors via secondary offering.

divestiture

70%

neutralMay 13

Termination of stockholders agreement ends PE-led board designation rights.

management change

60%

bearishMay 13

Complete exit of major private equity sponsors via secondary offering.

divestiture

70%

bullishMay 5

Swing from net loss to $26.6 million net income.

earnings beat

90%

bullishMay 5

Nordion segment margin increased to 56.4%.

margin expansion

70%

neutralMay 5

Significant long-term debt of $2.1B remains a primary balance sheet constraint.

debt restructure

40%

bearishMay 5

Ongoing EO tort litigation in multiple states with exhausted insurance coverage.

regulatory action

60%

bullishMay 5

Swing from net loss to $26.6 million net income.

earnings beat

90%

bullishMay 5

Nordion segment margin increased to 56.4%.

margin expansion

70%

neutralMay 5

Significant long-term debt of $2.1B remains a primary balance sheet constraint.

debt restructure

40%

bearishMay 5

Ongoing EO tort litigation in multiple states with exhausted insurance coverage.

regulatory action

60%

bullishMay 5

Swing from net loss to $26.6 million net income.

earnings beat

90%

bullishMay 5

Nordion segment margin increased to 56.4%.

margin expansion

70%

neutralMay 5

Significant long-term debt of $2.1B remains a primary balance sheet constraint.

debt restructure

40%

bearishMay 5

Ongoing EO tort litigation in multiple states with exhausted insurance coverage.

regulatory action

60%

bullishMay 5

Swing from net loss to $26.6 million net income.

earnings beat

90%

bullishMay 5

Nordion segment margin increased to 56.4%.

margin expansion

70%

neutralMay 5

Significant long-term debt of $2.1B remains a primary balance sheet constraint.

debt restructure

40%

bearishMay 5

Ongoing EO tort litigation in multiple states with exhausted insurance coverage.

regulatory action

60%

bullishMay 5

Swing from net loss to $26.6 million net income.

earnings beat

90%

bullishMay 5

Nordion segment margin increased to 56.4%.

margin expansion

70%

neutralMay 5

Significant long-term debt of $2.1B remains a primary balance sheet constraint.

debt restructure

40%

bearishMay 5

Ongoing EO tort litigation in multiple states with exhausted insurance coverage.

regulatory action

60%

bullishMay 5

Swing from net loss to $26.6 million net income.

earnings beat

90%

bullishMay 5

Nordion segment margin increased to 56.4%.

margin expansion

70%

neutralMay 5

Significant long-term debt of $2.1B remains a primary balance sheet constraint.

debt restructure

40%

bearishMay 5

Ongoing EO tort litigation in multiple states with exhausted insurance coverage.

regulatory action

60%

bullishMay 5

Swing from net loss to $26.6 million net income.

earnings beat

90%

bullishMay 5

Nordion segment margin increased to 56.4%.

margin expansion

70%

neutralMay 5

Significant long-term debt of $2.1B remains a primary balance sheet constraint.

debt restructure

40%

bearishMay 5

Ongoing EO tort litigation in multiple states with exhausted insurance coverage.

regulatory action

60%

Filing History

8-KMay 22, 2026

The 8-K filing confirms that Sotera Health has successfully navigated its 2026 annual meeting, maintaining board continuity and auditor ratification. While the headline results suggest a unified front, the disparity in support across different director nominees highlights a nuanced tension between broad institutional support and specific leadership critiques. For investors, the primary takeaway is a stabilized governance structure that is now tasked with converting this shareholder trust into tangible operational growth and shareholder value.

8-KMay 13, 2026

The filing details a fundamental shift in Sotera Health's ownership structure, marking the end of an era of private equity control. While the removal of the Stockholders Agreement simplifies corporate governance and removes the pressure of PE-driven exit timelines, the sheer volume of shares sold by the sponsors suggests a desire for a clean break. Investors must now weigh the benefit of increased management autonomy against the risk that the sponsors' departure signals a lack of confidence in the company's current trajectory.

10-QMay 5, 2026

The Q1 2026 filing presents a company at a crossroads between operational excellence and structural financial risk. On one hand, the transition to positive net income and the clearing of major legal hurdles provide a compelling narrative of a turnaround. The vertical integration of the Nordion and Sterigenics segments creates a high-barrier-to-entry moat that allows for premium pricing and dominant market positioning in the mission-critical sterilization space. However, the synthesis of the data suggests that the margin of safety remains thin. The reliance on non-GAAP measures like Adjusted EBITDA to mask the impact of high interest expenses and depreciation highlights the burden of the company's leverage. Investors must weigh the impressive top-line momentum and the resolution of specific legal cases against the systemic risk of remaining EO litigation and a debt-to-equity profile that leaves little room for error. The overall impact of the filing is a shift from 'existential legal crisis' to 'execution and deleveraging challenge.'